Toripalimab Clinical Trials
85 recruitingDrug
Phase 263Phase 116Phase 311Not Applicable5Early Phase 11Phase 41
Showing 1–20 of 85 trials
Recruiting
Phase 4
A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic Nasopharyngeal Cancer
Nasopharyngeal Cancer Recurrent
Coherus Oncology, Inc.100 enrolled13 locationsNCT06457503
Recruiting
Phase 1
A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
Advanced Solid TumorMetastatic Solid Tumor
Coherus Oncology, Inc.154 enrolled30 locationsNCT06657144
Recruiting
Phase 2
KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal Cancer
Esophageal Squamous Cell Carcinoma (ESCC)
Beijing Konruns Pharmaceutical Co., Ltd.60 enrolled1 locationNCT07481058
Recruiting
Phase 2
The Effect of Toripalimab Plus Radiotherapy in Patients With Operable Stage II-IIIA (N+) Non Small Cell Lung Cancer
NSCLC
Shanghai Chest Hospital124 enrolled1 locationNCT05798845
Recruiting
Phase 2
Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-escalation (NeoScorch HN)
Head and Neck CancerLaryngeal CancerOral Cavity Cancer+6 more
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins75 enrolled1 locationNCT07209189
Recruiting
Phase 2
A Single-center Phase II Study to Investigate the Immune Maintenance Therapy Pattern in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Who Have Achieved MPR After Neoadjuvant Immunotherapy Combined With Chemotherapy
Head and Neck Cancer
Tianjin Medical University Cancer Institute and Hospital268 enrolled1 locationNCT06208826
Recruiting
Phase 1Phase 2
Combination Immunotherapy for the Treatment of Chemotherapy-refractory Metastatic MSS CRC
Metastatic Microsatellite Stable Colorectal Carcinoma
Dan Feng24 enrolled1 locationNCT07281716
Recruiting
Phase 2
Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer
Ovarian Cancer
Canadian Cancer Trials Group60 enrolled7 locationsNCT04918186
Recruiting
Phase 2
Gemcitabine + Docetaxel + Toripalimab Induction in Epstein-Barr Virus (EBV) Associated Nasopharyngeal Carcinoma(NPC)
Nasopharyngeal Carcinoma
Stanford University24 enrolled1 locationNCT06592599
Recruiting
Phase 2
A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma
Hepatocellular Carcinoma
Coherus Oncology, Inc.72 enrolled44 locationsNCT06679985
Recruiting
Phase 2
Toripalimab in Combination With Standard Treatment for Human Papillomavirus (HPV) Positive Throat Cancer
Oropharyngeal Cancer
University of Chicago30 enrolled1 locationNCT07290621
Recruiting
Phase 1Phase 2
A Phase I/IIa Study of AL8326 Combined With Toripalimab in the Treatment of Advanced Solid Tumors.
Solid Tumor
Advenchen Laboratories, LLC228 enrolled15 locationsNCT07392736
Recruiting
Phase 3
Proton vs Photon IMRT in Locally Advanced Nasopharyngeal Carcinoma: A Phase III Trial
Nasopharyngeal Carcinoma (NPC)
Man Hu300 enrolled1 locationNCT07340515
Recruiting
Phase 2
Nimotuzumab Combined With Toripalimab and Chemotherapy for Locally Advanced Tonsillar Cancer
Head & Neck Cancer
Tang-Du Hospital10 enrolled1 locationNCT07353723
Recruiting
Phase 2
The Optimal Radioimmunotherapy Combinations for Advanced TNBC
Sun Yat-sen University60 enrolled1 locationNCT06735131
Recruiting
Phase 3
Adaptive Immunotherapy for Nasopharyngeal Carcinoma
Nasopharyngeal Cancinoma (NPC)
Sun Yat-sen University802 enrolled1 locationNCT07154069
Recruiting
Phase 1Phase 2
A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.
Recurrent or Metastatic Nasopharyngeal Carcinoma
MediLink Therapeutics (Suzhou) Co., Ltd.202 enrolled20 locationsNCT07258979
Recruiting
Phase 2
DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer
Breast Cancer
RemeGen Co., Ltd.40 enrolled1 locationNCT06178159
Recruiting
Phase 2
A Study of ES102 in Combination With Toripalimab in Subjects With Advanced Non-small Cell Lung Cancer
Elpiscience (Suzhou) Biopharma, Ltd.40 enrolled9 locationsNCT06623136
Recruiting
Phase 2
Immunotherapy (Toripalimab) for Reducing Recurrence Risk After Surgery for Mismatch Repair Deficient Stage IIB, IIC, or III Colon Cancer
Stage III Colon Cancer AJCC v8Localized Colon CarcinomaStage IIB Colon Cancer AJCC v8+1 more
Emory University40 enrolled5 locationsNCT07140679